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OBJECTIVES: Misuse of anabolic androgenic steroids in athletes is a strategy used to enhance strength and
skeletal muscle hypertrophy. However, its abuse leads to an imbalance in muscle sympathetic nerve activity,
increased vascular resistance, and increased blood pressure. However, the mechanisms underlying these alterations
are still unknown. Therefore, we tested whether anabolic androgenic steroids could impair resting baroreflex
sensitivity and cardiac sympathovagal control. In addition, we evaluate pulse wave velocity to ascertain the arterial
stiffness of large vessels.
METHODS: Fourteen male anabolic androgenic steroid users and 12 nonusers were studied. Heart rate, blood
pressure, and respiratory rate were recorded. Baroreflex sensitivity was estimated by the sequence method,
and cardiac autonomic control by analysis of the R-R interval. Pulse wave velocity was measured using a non-
invasive automatic device.
RESULTS:Mean spontaneous baroreflex sensitivity, baroreflex sensitivity to activation of the baroreceptors, and
baroreflex sensitivity to deactivation of the baroreceptors were significantly lower in users than in nonusers. In the
spectral analysis of heart rate variability, high frequency activity was lower, while low frequency activity was
higher in users than in nonusers. Moreover, the sympathovagal balance was higher in users. Users showed higher
pulse wave velocity than nonusers showing arterial stiffness of large vessels. Single linear regression analysis
showed significant correlations between mean blood pressure and baroreflex sensitivity and pulse wave velocity.
CONCLUSIONS: Our results provide evidence for lower baroreflex sensitivity and sympathovagal imbalance
in anabolic androgenic steroid users. Moreover, anabolic androgenic steroid users showed arterial stiffness.
Together, these alterations might be the mechanisms triggering the increased blood pressure in this population.
KEYWORDS: Autonomic Nervous System; Blood Pressure; Baroreflex Sensitivity; Pulse Wave Velocity.
’ INTRODUCTION
Misuse of anabolic androgenic steroids (AASs) in body-
building athletes is a common strategy to enhance strength
and skeletal muscle hypertrophy. However, AASs are asso-
ciated with negative impacts on health, such as muscle
sympathetic hyperactivation, reduced vasodilatation, and
increased blood pressure (BP) (1-3). On the other hand, the
exact mechanisms involved in these alterations in AAS user
(AASU) athletes are still unknown.
In several cardiovascular diseases such as hypertension
and heart failure, lower baroreflex sensitivity (BRS) is one of
the main mechanisms leading to increased sympathetic
hyperactivation (4-6). Increased systemic arterial pressure
activates the arterial baroreceptors leading to bradycardia
and decreased peripheral vascular resistance (parasympa-
thetic predominance). On the other hand, decreased systemic
arterial pressure deactivates the baroreceptors leading to
tachycardia and an increase in vascular resistance (sympa-
thetic predominance) (5).
In a previous microneurography study, it was demon-
strated that AASUs showed higher muscle sympathetic
nerve activity (MSNA) than AAS nonusers (AASNUs) (2).
In fact, it was demonstrated by single linear regression
analysis that the mean BP had a strong correlation with
MSNA. Moreover, a decreased resting forearm blood flow
was found in AASUs (2). Experimental studies support
the concept that rats treated with AASs showed hyperten-
sion associated with impaired BRS control of the heart
rate (7). Consequently, the increased BP observed in AASU
athletes could be related to impaired BRS, which is used
to control BP.
Likewise, rats treated with high doses of AASs showed
dysfunction in tonic cardiac autonomic regulation, as eval-
uated by spectral analysis of heart rate variability (8,9).
These results demonstrated the existence of a relationshipDOI: 10.6061/clinics/2018/e226
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between AAS misuse and imbalance in autonomic control
(of both the periphery and the heart).
Therefore, the present study was performed to test whether
AASU athletes showed impaired BRS and an imbalance in
cardiac sympathovagal control. In addition, we evaluated
pulse wave velocity (PWV) to ascertain the arterial stiffness
of large vessels.
’ MATERIALS AND METHODS
Study design
This is a prospective, cross-sectional comparison study of
AASUs and AASNUs. This study was designed to ascertain
the influence of AASs on BRS, cardiac autonomic control,
and PWV. To show the effect of AASs on these parameters,
all the measurements were obtained when the subjects were
at the peak of their AAS use. To avoid the influence of exercise
on the measurements, all participants were instructed to
refrain from exercise 48 hours before the experimental
protocol. Moreover, they abstained from caffeine-containing
products, fatty foods, and any sports supplements for at least
24 hours before the measurements.
In the present study, from November 2013 to January 2015,
14 male AASUs and 12 healthy age-matched male AASNUs
were invited to participate.
Anamnesis was taken from all participants to obtain
information about their exercise training regime, AAS usage,
medications, and eating habits, e.g., use of dietary supple-
ments and percentages of macronutrients (e.g., proteins and
carbohydrates).
The inclusion criteria for both groups were 1) healthy
subjects and 2) strength training (hypertrophy) for at least
2 years. Exclusion criteria for both groups were 1) smoking,
2) alcohol intake, 3) use of medication (e.g., diuretics and
anti-hypertensives), and 4) liver and kidney disease.
All the measurements were obtained when the subjects
were at the peak of their AAS use (between 4-6 weeks, self-
administering, maximum dosage, and self-reported). The
AAS cycles of the AASU group lasted from 8-12 weeks.
In addition, the subjects had been using AASs for at least
2 years with 2-4 cycles per year. The self-reported most used
AASs were stanozolol, testosterone propionate, testosterone
cypionate, nandrolone decanoate, boldenone undecylenate,
and methenolone enanthate.
The study protocol was approved by the Local Human
Subject Protection Committee (number 569.389), and written
consent was given by each individual. The study was per-
formed in accordance with the principles of the Declaration
of Helsinki.
All participants were enrolled in traditional bodybuilding
strength-training exercises consisting of 3-4 sets of 8-12 repe-
titions for approximately 2-4 exercise muscle groups 5 days
per week. Division of the training consisted of 2-3 muscle
groups exercised per day (e.g., training A: chest, triceps brachii,
and shoulders; training B: back and biceps brachii; training
C: legs). All participants were asked about their perceived
exertion during the training sessions, which should have been
8 to 10 (hard to extremely hard) in accordance with OMNI-
Resistance Exercise Scale (OMNI-RES) (10). Both groups had
trained for 8 years on average.
Heart rate, arterial pressure, and respiratory rate
For 10 minutes of baseline recording, the heart rate was
monitored continuously through lead II of an electrocardiogram.
Simultaneously, arterial blood pressure (systolic blood pres-
sure, SBP; diastolic blood pressure, DBP; and mean blood
pressure, MBP) was monitored using a Finometer PROs
(Finapress Medical System), which provides noninvasive
measurement of the beat-to-beat BP. Respiratory rate was
monitored using a piezoelectric thoracic belt (Pneumotrace
II, model 1132, Respiration Transducer, UFI, USA) placed
around the upper abdomen.
Spontaneous BRS was determined using the sequence
method (11), which consists of the identification of 3 or more
consecutive beats in which progressive increases or decreases
in SBP are followed by progressive lengthening or shortening
of the RR interval during spontaneous behavior. Consecutive
and concomitant BP increases represent spontaneous activa-
tion of the baroreceptors (up sequences; BRS+), and decreases
in BP represent spontaneous deactivation of the barorecep-
tors (down sequences; BRS-). The threshold values for includ-
ing beat-to-beat SBP and RR interval changes in a sequence
were set at 1 mm Hg and 3 ms, respectively. The reflex
sensitivity was evaluated by computing the slope of the
regression line between changes in SBP and RR interval.
The average of all computed slopes was used to obtain the
BRS (5). Finometer PROs has a 1 second delay to convert the
analogic signal to digital signal. To correct this delay between
RR interval and SBP, we extracted similar and correspondent
amounts of RR interval and SBP. Signals refer to sequences
during which the SBP and RR interval of the following beat
changed in the same direction, either increasing or decreas-
ing (baroreflex sequences).
Cardiac autonomic evaluation
The electrocardiogram signal to extract the time series for
the heart rate (RR interval) and the beat-to-beat BP were
recorded with a computer program (Windaq, sampling freq-
uency of 500 Hz and a resolution of 16 bits). The cardio-
vascular RR interval fluctuation was assessed in the frequency
domain using autoregressive spectral analysis as descri-
bed previously (12,13). For stationary segments of the time
series, autoregressive parameters were assessed via Levinson–
Durbin recursion, and the order of the model was selected
according to Akaike’s criterion (12,13). After that, auto-
regressive spectral decomposition was performed. This
procedure permitted the automatic quantification of the
center frequency and the power of each relevant component
in absolute normalized units (n.u.). Low frequency (LF)
components (0.04-0.15 Hz) indicated the predominance of
sympathetic modulation. High frequency (HF) components
(0.15 and 0.4 Hz), synchronized with the breathing signals,
were considered parasympathetic modulation. The power
spectrum (absolute; abs.) is indicated in ms2, and the power
spectral density is calculated in n.u. The normalization was
performed by dividing the power of the LF or HF component
by the total spectral power, as previously described (12,13).
The ratio of LF to HF (LF/HF) was calculated as cardiac
sympathovagal balance.
The breathing was spontaneous, and the breathing of
2 AASU and 1 AASNU subjects was uncoupled in the HF
range; these subjects were excluded from the cardiac auto-
nomic evaluation.
Pulse wave velocity (PWV)
Carotid-femoral PWV was measured using a noninvasive
automatic device (Complior SPs, Artech Medical, Pantin, France)
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as previously described (14). The pressure waveforms were
recorded in the common carotid artery and femoral artery
using a pressure-sensitive transducer. The PWVwas calculated
by the formula: PWV=D/t, where ‘‘D’’ means the distance
between the recording sites, and ‘‘t’’ is the pulse transit time.
During 10 different cardiac cycles, the measurements were
repeated, and the mean was used in the analysis. The exper-
iment was performed as previously suggested (15).
Experimental protocol
All procedures were performed in a quiet, temperature-
controlled (21oC) room in the morning at approximately the
same time of day. All measurements were assessed in the
supine position. The participants were instructed to restrain
from exercise 48 hours before the experimental protocol and
to eat their breakfast normally. However, they abstained from
caffeine-containing products, fatty foods, and any sports
supplements for at least 24 hours before the measurements.
Statistics
Normality (Shapiro-Wilk) and homogeneity (Levene) tests
were conducted to test the distribution of the data. Data are
presented as the mean± SD or median (interquartile range –
IQR – 25%-75%). Possible differences between groups were
analyzed using an unpaired Student’s t-test or Mann-
Whitney-Wilcoxon test for parametric or nonparametric
data, respectively.
Univariate correlation (Pearson correlation) between MBP,
age, BRS-, BRS+, mean BRS, PWV, LF, HF, and LF/HF was
conducted to test the association between parameters.
An analysis of covariance (ANCOVA) was conducted
to test the possible influence of age and body mass index
(BMI) on MBP and mean BRS. Differences were considered
significant at po0.05. All data were analyzed using SPSS
version 18.0.
’ RESULTS
The physical characteristics, heart rate, BP, and PWV are
shown in Table 1. There were no significant differences
between AASUs and AASNUs in age and height. However,
AASUs showed higher weight, BMI, heart rate, SBP, DBP,
MBP, and PWV than AASNUs. After controlling for cofactors,
ANCOVA showed no significant differences in MBP for age
(p=0.47) or BMI (p=0.13).
The spontaneous BRS and heart rate variability are shown
in Table 2. The mean spontaneous BRS, spontaneous BRS+,
and spontaneous BRS- were lower in AASUs than in AASNUs.
After controlling for cofactors, ANCOVA showed no signifi-
cant differences in mean spontaneous BRS for age (p=0.23)
or BMI (p=0.94). For the heart rate variability, there were
no significant differences between AASUs and AASNUs in
the variance and LFabs. Notably, AASUs showed lower HFabs
and HFn.u., whereas LFn.u. was higher, indicating cardiac
sympathetic hyperactivation and loss of cardiac parasympa-
thetic control in this group.
Single linear regression analysis showed significant correla-
tions between MBP and BRS+, mean BRS, and PWV (Table 3).
However, age, BRS-, LF, HF, and LF/HF were not correlated
with MBP (Table 3).
’ DISCUSSION
Our study evaluated the influence of AASs on BRS
and cardiac autonomic control to investigate their potential
roles in the mechanisms underlying increased BP in athletes
misusing AASs. In addition, we evaluated arterial stiffness
by PWV. Our main findings were that spontaneous BRS and





*Mean BRS, ms/mmHg 15.31 (8.36-16.73) 22.87 (14.57-25.63) 0.01
BRS+, ms/mmHg 14.68 (8.61-17.47) 24.07 (11.56-31.43) 0.03
BRS-, ms/mmHg 13.47±3.91 19.25±5.68 0.005
N 12 11
Cardiac autonomic control RRi
Variance, ms2 3.264 (1604-4820) 3.463 (1717-6056) 0.53
LFabs., ms
2 715 (370-1358) 1.269 (949-1406) 0.16
HFabs., ms
2 377 (138-651) 746 (432-2313) 0.03
HF, n.u., % 36.37 (25.91-40.90) 40.44 (28.60-63.11) 0.04
LF, n.u., % 67.10 (59.75-76.67) 59.55 (36.88-71.40) 0.04
LF/HF 2.40 (1.44-3.45) 1.40 (0.55-2.55) 0.04
*Values ANCOVA adjusted (for age and BMI). Data are presented as the mean±SD or median±IQR (25%-75%; IQR=interquartile range).
AASNU=anabolic androgenic steroid nonuser, AASU=anabolic androgenic steroid user, BRS+=spontaneous baroreflex sensitivity increases,
BRS-=spontaneous baroreflex sensitivity decreases, RRi=R-R interval, LF=low frequency, HF=high frequency, abs.=absolute, n.u.=normalized unit.
Table 1 - Physical characteristics, heart rate, blood pressure,
and pulse wave velocity in anabolic androgenic steroid users
and anabolic androgenic steroid nonusers.
AASU AASNU p
N 14 12
Age, years 34±7 30±4 0.11
Weight, kg 89±8 80±5 0.002
Height, m 1.76±0.07 1.78±0.07 0.50
BMI, kg/m2 29±3 25±2 0.001
Heart rate, bpm 68±9 56±7 0.002
SBP, mmHg 127±13 117±7 0.03
DBP, mmHg 75±7 66±5 0.003
*MBP, mmHg 94±9 84±6 0.005
PWV, m/s 9.56±0.91 8.58±1.20 0.03
*Values ANCOVA adjusted (for age and BMI). Data are presented as the
mean±SD. AASNU=anabolic androgenic steroid nonuser, AASU=anabolic
androgenic steroid user, BMI=body mass index, SBP=systolic blood
pressure, DBP=diastolic blood pressure, MBP=mean blood pressure,
PWV=pulse wave velocity.
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cardiac sympathovagal balance were impaired in AASUs
compared to AASNUs. Moreover, we found a correlation
between BP and spontaneous BRS and arterial stiffness.
In older subjects, a reduction in arterial compliance is
one of the main mechanisms of impaired cardiovagal BRS
(16,17). Baroreceptors are located at the carotid sinus and
aortic arch, and these receptors can be influenced by the
compliance of these elastic arteries (18), which could explain,
at least in part, the decreased BRS observed in our study.
Baroreceptors control moment-to-moment variations in
BP by mechanical transduction of pressure into barosensory
vessel stretch and neural transduction of stretch into vagal
outflow (19,20). BRS inefficiency in hypertension leads to
sympathetic hyperactivity and increased BP (21). In the pre-
sent study, although the BP of AASUs was not in the hyper-
tension range (SBP/DBP: 127/75 mmHg), it was different
from that of the age-matched control group (SBP/DBP: 117/
66 mmHg). The beat-to-beat BP measurement in this study
was performed in a quiet room with the subjects lying down
for the baseline condition, which does not reflect their daily
life. A higher 24-hour BP has been observed in AASUs (2),
and this result may have greater relevance to real life. Some-
how, this slight increase in BP could be associated with
alterations in BRS in this population.
Another interesting finding of our study was that AASUs
showed higher PWV than AASNUs. Assessment of arterial
stiffness is a recommended measurement in the European
Society of Cardiology guidelines because PWV is associated
with future fatal and nonfatal cardiovascular events, even
in younger people (22). In our study, this parameter was
different in AASUs, and it may indicate increased risk for
cardiovascular disease. Arterial stiffness is directly correlated
with poor cardiac outcomes in the general population (22).
PWV provides information about arterial segment stiffness
(23), and in the present study, PWV was higher, suggesting
that arterial stiffness worsens hemodynamic problems in
young male AASUs.
Autonomic imbalance in AASUs, especially muscle sym-
pathetic hyperactivation, was previously demonstrated (2);
however, whether AASs could alter cardiac autonomic
control in humans was unknown. As demonstrated in the
present study, the cardiac sympathetic and parasympathetic
activities were impaired in AASUs. Indeed, we observed
cardiac sympathetic predominance, as indicated by the
elevated LF n.u. and LF/HF, in AASUs than in AASNUs.
Elevated sympathetic nerve activity is known to increase
cardiovascular risk and mortality in some pathological
conditions, such as hypertension (24) and heart failure (25).
Previous studies showed higher BP at rest (2) and during
exercise (26) in AASUs, and elevated MSNA was positively
correlated (r=0.75, p=0.002) with elevated mean 24-hour
BP (2), suggesting a potential mechanism for hemodynamic
alteration. Moreover, cardiac parasympathetic control, as
measured by the HF component (n.u.), was significantly lower
in the AASUs than in AASNUs. This result is consistent with
a recent study that showed that AASUs had lower heart rate
recovery after maximal exercise (27), which is a marker of
poor vagal reactivation (28). Taken together, these results
(delay in heart rate recovery and lower HF) show impaired
cardiac parasympathetic control in AASUs.
There are several studies showing that higher BMI in over-
weight and obese populations is associated with increased
sympathetic nerve activity (29). In our study, we found that
AASUs presented with BMIs of 29±3 kg/m2, which could
influence sympathetic outflow and, consequently, BP. How-
ever, when we performed an ANCOVA to test the possible
influence of BMI on MBP, we observed no significant differ-
ences (p=0.13), showing that BMI is not correlated with
higher BP in AASUs. In fact, higher BMI in bodybuilders is
due to higher muscle mass than fat mass (30).
We recognized limitations in our study. We do not know if
these results persist if the baroreflex is tested using vaso-
active drugs, such as phenylephrine and sodium nitroprus-
side. We did not compare our results to a sedentary control
group, and we are cautious about drawing conclusions from
our study group only compared to a strength-training exercise
group without AAS use. However, our results show alter-
ations in BRS, cardiac autonomic nervous system, and BP in
AASUs. Someone could argue that strength-training exercise,
especially acute bouts of exercise, could influence arterial
stiffness. However, all participants were instructed to refrain
from exercise 48 hours before the experimental protocol.
We did not perform body composition measurements in the
participants. However, all of them were strength athletes,
and they visually presented large muscle mass and low fat
composition. Finally, although we demonstrated a correla-
tion between BP and BRS in AASUs, we cannot at this
moment support a cause-effect relationship. Future studies
should be designed to address this issue.
In conclusion, our results provide evidence for lower
BRS and sympathovagal imbalance in AASUs. Moreover,
AASUs showed arterial stiffness. Together, these alterations
might be the mechanisms triggering the increased BP in this
population.
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Table 3 - Single linear regression (Pearson) with mean blood
pressure serving as the dependent variable.
Variables R P
Age, years 0.28 0.11
BRS+, ms/mmHg -0.41 0.03
BRS-, ms/mmHg -0.23 0.15
Mean BRS, ms/mmHg -0.38 0.04
PWV, m/s 0.49 0.01
LF, n.u., % 0.28 0.11
HF, n.u. % -0.28 0.11
LF/HF 0.33 0.64
BRS+=spontaneous baroreflex sensitivity increases, BRS-=spontaneous
baroreflex sensitivity decreases, PWV=pulse wave velocity, LF=low
frequency, HF=high frequency, n.u.=normalized unit.
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